Immunology and Microbiology
DNA Vaccine
100%
Cytotoxic T-Cell
91%
Vaccine Efficacy
81%
Mouse
72%
Human Papillomavirus Type 16
60%
Wart Virus
57%
Immune Response
56%
Antigen Specificity
52%
Vaccination Policy
51%
Calreticulin
33%
T Cell
30%
DNA Vaccination
30%
Dendritic Cell
30%
Immunotherapy
26%
Tumor Cell
23%
Epitope
19%
Cancer Immunotherapy
19%
Tumor Antigen
18%
Adoptive Immunity
16%
T-Helper Cell
16%
Cervarix
14%
Heat Shock
11%
Electroporation
11%
CD8
10%
Adaptive Immune System
10%
MHC Class I
10%
Vaccinium
10%
Cytotoxic T Cell
9%
Transgenic Mouse
9%
Sindbis Virus
9%
Replicon
8%
RNA Interference
8%
Interleukin 2
8%
Precursor
8%
C57BL 6 Mouse
8%
Proteasome
8%
Phosphoryl Lipid A
7%
Mouse Model
7%
Antigen-Presenting Cell
7%
Mycobacterium Tuberculosis
7%
Natural Killer Cell
7%
CD4
7%
Antigen Presentation
7%
Wild Type
7%
Vaccinia Virus
6%
HPV Vaccine
6%
Immune Tolerance
6%
Immunogenicity
6%
Cancer Cell
6%
Papillomaviridae
6%
Keyphrases
DNA Vaccine
75%
Tumor
41%
High-risk Human Papillomavirus (HR-HPV)
40%
CD8+ T Cells
36%
Antitumor Effect
36%
Vaccine Potency
29%
HPV16
28%
Calreticulin
25%
Dendritic Cells
23%
Vaccination
22%
Cervical Cancer
22%
Ovarian Cancer
21%
DNA Vaccination
20%
Human Papillomavirus Vaccine
20%
Tumor Immunity
20%
Antigen-specific
15%
HPV16 E7
14%
CD8+ T
13%
Tumor Cells
13%
Immune Response
12%
Cancer Immunotherapy
12%
DNA Encoding
12%
Tumor Antigen
12%
HPV DNA
11%
Cell-mediated Immune Response
11%
Human Papillomavirus DNA
10%
Intracellular Targeting
8%
Papillomavirus Infections
8%
Vaccine Target
8%
Therapeutic Effect
8%
Tumor Microenvironment
8%
Transgenic Mice
8%
Associated Diseases
7%
Cell Life
7%
E7 Antigen
7%
Targeting Strategies
7%
HLA-A2
7%
TC-1 Tumor
7%
Epitope
7%
Interleukin-2
7%
Vaccinium
7%
Response Effects
7%
LAMP2
6%
Specific Immunotherapy
6%
Tumor-bearing Mice
6%
Electroporation
6%
TC-1
6%
MHC Class II
6%
Rpn13
6%
Cancer Treatment
6%
Pharmacology, Toxicology and Pharmaceutical Science
DNA Vaccine
63%
Neoplasm
59%
Human Papillomavirus
50%
CD8 Antigen
44%
Vaccination Policy
43%
Malignant Neoplasm
41%
Mouse
34%
Human Papillomavirus Type 16
34%
Vaccine
28%
Immunotherapy
22%
Wart Virus Vaccine
21%
Ovary Cancer
21%
Uterine Cervix Cancer
21%
Calreticulin
15%
Disease
14%
Infection
11%
Papillomavirus Infection
9%
Cisplatin
9%
Therapeutic Effect
9%
Epitope
7%
Tumor Antigen
7%
Protein E7
7%
Protein E6
7%
Heat Shock Protein 70
7%
Clinical Trial
6%
Chemotherapy
6%
Tumor Model
6%
Ovary Tumor
6%
Cancer Model
5%
Interleukin 2
5%
Tumor Growth
5%
Antiapoptotic
5%
Fusion Protein
5%
Paclitaxel
5%
SARS Coronavirus
5%
Mesothelin
5%